Phase 2 trial of ibrutinib in previously untreated high-risk smoldering mantle cell lymphoma.
Gaulin C, Jain P, Nair R, Iyer SP, Lee HJ, Fayad L, Feng L, Ok CY, Kanagal-Shamanna R, Oriabure O, Chen W, Xu G, Deswal A, Iliescu C, Badillo M, Ky M, Avellaneda M, Tangc G, Medeiros LJ, Vega F, Flowers CR, Wang ML.
Gaulin C, et al. Among authors: lee hj.
Leuk Lymphoma. 2025 Jan 21:1-5. doi: 10.1080/10428194.2025.2454540. Online ahead of print.
Leuk Lymphoma. 2025.
PMID: 39838574
No abstract available.